ONO PHARMACEUTICAL : Phase 3 BEACON CRC Safety Lead-In Results in BRAF-Mutant Colorectal Cancer Presented at European Society for Medical Oncology Congress (31.1KB)

September 13, 2017

Boulder, Colo., (September 8, 2017) - Array BioPharma (Nasdaq: ARRY) and Pierre Fabre announced safety results and initial clinical activity from the safety lead-in of the Phase 3 BEACON CRC study evaluating binimetinib, a MEK inhibitor, encorafenib, a BRAF inhibitor and Erbitux® (cetuximab), an anti-EGFR antibody, in patients with BRAF-mutant colorectal cancer (CRC) whose disease has progressed after one or two prior regimens in the metastatic setting. BRAF-mutant CRC represents a difficult-to-treat subtype of colorectal cancer that impacts 10 to 15% of CRC patients. These data were presented as an e-poster on September 8 at the 2017 European Society for Medical Oncology Congress in Madrid, Spain (Abstract No. #517P).

Ono Pharmaceutical Co., Ltd. ("ONO") entered into the license agreement with Array BioPharma Inc. regarding binimetinib, a MEK inhibitor and encorafenib, a BRAF inhibitor in May 2017 and received rights to develop and commercialize both products in Japan and South Korea.

Binimetinib and encorafenib are currently in two global Phase 3 clinical trials for the treatment of patients with BRAF-mutant melanoma (COLUMBUS study including Japan and South Korea) and BRAF-mutant colorectal cancer (BEACON CRC study including South Korea) as a combination therapy.

Please click here for the press release distributed by Array BioPharma Inc.

ONO PHARMACEUTICAL CO., LTD.

Corporate Communications Public_relations@ono.co.jp